Changing the Timing of Enzalutamide Intake from Morning to before Sleep at Night Overcame Enzalutamide-Induced Dysgeusia
نویسندگان
چکیده
منابع مشابه
Enzalutamide in metastatic prostate cancer before chemotherapy.
BACKGROUND Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not received chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy. METHODS...
متن کاملPractical guide to the use of enzalutamide.
INTRODUCTION We summarize the development, definitive trials, and practical use of enzalutamide for practicing urologists and medical oncologists. The care paradigm for patients with metastatic castration resistant prostate cancer (mCRPC) is a changing landscape, with the ongoing discovery of drivers of cancer progression yielding actionable targets for drug development. Since 2010, sipuleucel-...
متن کاملEnzalutamide in metastatic prostate cancer before chemotherapy. - PubMed - NCBI
Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not received chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy. In this double-blind...
متن کاملClinical Pharmacokinetic Studies of Enzalutamide
BACKGROUND AND OBJECTIVES Oral enzalutamide (160 mg once daily) is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This article describes the pharmacokinetics of enzalutamide and its active metabolite N-desmethyl enzalutamide. METHODS Results are reported from five clinical studies. RESULTS In a dose-escalation study (n = 140), enzalutamide half-life w...
متن کاملEnzalutamide: the emperor of all anti-androgens
www.amepc.org/tau © Translational Andrology and Urology. All rights reserved. In the last few years, there has been a rekindled interest in the androgen receptor (AR) and AR signaling as valid therapeutic targets in prostate cancer. While the primary goal of therapy for recurrent or advanced prostate cancer has long been to reduce circulating and intratumoral androgen levels, recent laboratory ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Case Reports in Oncology
سال: 2019
ISSN: 1662-6575
DOI: 10.1159/000502054